Healthcare Services

Mycosis Fungoides Treatment Market Revenue Growth Expected to Reach $1.37 Billion by 2030 with 5.7% CAGR

April 2, 2026April 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Mycosis Fungoides Treatment Market Across 2026–2030?

The mycosis fungoides treatment market size has demonstrated substantial growth over recent years. It is anticipated to increase from $1.03 billion in 2025 to $1.1 billion in 2026, registering a compound annual growth rate (CAGR) of 6.7%. The expansion observed during the historical period stems from factors including restricted treatment options, the escalating prevalence of cutaneous t-cell lymphoma, a reliance on radiation therapy, instances of delayed diagnosis, and the dependence on topical steroids.

The mycosis fungoides treatment market size is anticipated to experience significant expansion in the coming years. Projections indicate it will reach $1.37 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.7%. This forecasted growth is attributable to several factors, including the advancement of targeted therapies, the increasing application of immunotherapy, the establishment of more dermatology oncology centers, enhanced diagnostic capabilities, and greater investment in research for rare cancers. Furthermore, major trends identified for the forecast period include the rising adoption of combination therapy approaches, increased use of topical steroids for early-stage management, a growing preference for targeted therapies and immunotherapy, the expansion of available photodynamic and radiation therapy options, and a higher demand for specialized dermatology and oncology clinics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15613&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Mycosis Fungoides Treatment Market?

The increasing occurrence of lymphoma cancer is anticipated to drive the expansion of the mycosis fungoides treatment market in the future. Lymphoma is defined as a malignancy affecting the lymphatic system, encompassing components such as lymph nodes, the spleen, the thymus gland, and bone marrow. The rise in lymphoma cancer cases can be attributed to multiple contributing elements, among them environmental exposures, a surge in viral infections, the growing elderly demographic, and various lifestyle choices. To manage cutaneous T-cell lymphomas, treatments for mycosis fungoides, including topical corticosteroids, phototherapy, and systemic therapies, are employed. The objective of these therapeutic approaches is to mitigate skin lesions, alleviate symptoms, and control the advancement of the disease in individuals with lymphoma. As an illustration, the American Cancer Society, a US-based non-profit organization, reported in January 2024 that non-Hodgkin lymphoma (NHL) constituted one of the most prevalent cancers in the United States, representing approximately 4% of all cancer diagnoses. Projections indicated that roughly 80,620 individuals (comprising 44,590 males and 36,030 females) were expected to be diagnosed with NHL, while around 20,140 individuals (consisting of 11,780 males and 8,360 females) were predicted to succumb to this cancer in 2024. Consequently, the increased occurrence of lymphoma cancer is propelling the expansion of the mycosis fungoides treatment market.

What Segmentation Levels Are Considered In The Mycosis Fungoides Treatment Market?

The mycosis fungoides treatment market covered in this report is segmented –

1) By Drug Type: Topical Steroids, Mechlorethamine

2) By Treatment Type: Photodynamic Therapy, Radiation Therapy, Targeted Therapy, Chemotherapy

3) By End-user: Hospitals, Private Clinics, Specialty Clinics

Subsegments:

1) By Topical Steroids: Corticosteroid Creams Or Ointments ( Hydrocortisone, Clobetasol), Topical Steroid Lotions

2) By Mechlorethamine: Topical Mechlorethamine ( Nitrogen Mustard Cream), Injectable Mechlorethamine

Which Trends Are Shaping The Future Of The Mycosis Fungoides Treatment Market?

Companies operating in the mycosis fungoides treatment market are prioritizing the creation of advanced solutions, specifically targeted immunotherapy, to improve both treatment efficacy and patient well-being. This immunotherapy selectively targets malignant and regulatory T-cells, sparing healthy tissue, which leads to quicker disease management and fewer side effects. An example of this advancement is Citius Pharmaceuticals, a US-based biopharmaceutical company, announcing in August 2024 the FDA’s approval of LYMPHIR (denileukin diftitox-cxdl), an IL-2 receptor-targeted immunotherapy. This therapy received approval for adult patients suffering from relapsed or refractory cutaneous T-cell lymphoma, including mycosis fungoides, who have undergone at least one previous systemic treatment. LYMPHIR functions through a unique mechanism, directly eliminating malignant T-cells and reducing Tregs, thereby enhancing the immune system’s response. Clinical trials showed a 36% objective response rate, with a quick median time to response of 1.4 months. The treatment successfully reduced skin disease in 84% of patients and alleviated pruritus without causing cumulative toxicity. LYMPHIR presents a distinct systemic treatment option for Stage I-III patients, fulfilling a crucial need for effective therapies in a patient group with few other choices.

Which Leading Firms Are Contributing To The Growth Of The Mycosis Fungoides Treatment Market?

Major companies operating in the mycosis fungoides treatment market are Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Tocris Bioscience, Viatris Inc., Astellas Pharma Inc., Daiichi Sankyo Company, Takeda Pharmaceutical Company Limited, Bausch Health, Eisai Co. Ltd., Horizon Therapeutics plc, Varian Medical Systems, Kyowa Kirin Co. Ltd., Seattle Genetics Inc., Azurity Pharmaceuticals Inc., Innate Pharma S.A., Helsinn Therapeutics, Jubilant Cadista Pharmaceuticals Inc., Elorac Inc., Soligenix Inc., Ceptaris Therapeutics Inc.

Read the full mycosis fungoides treatment market report here:

https://www.thebusinessresearchcompany.com/report/mycosis-fungoides-treatment-global-market-report

Which Regions Are Projected To Dominate The Mycosis Fungoides Treatment Market In The Coming Years?

North America was the largest region in the mycosis fungoides treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mycosis fungoides treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Mycosis Fungoides Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15613&type=smp

Browse Through More Reports Similar to the Global Mycosis Fungoides Treatment Market 2026, By The Business Research Company

In Vitro Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report

Immunoglobulin E Ige Allergy Blood Tests Global Market Report

https://www.thebusinessresearchcompany.com/report/immunoglobulin-e-ige-allergy-blood-tests-global-market-report

Immunodiagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/immunodiagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795